On December 27, 2017, Teva Pharmaceuticals (TEVA) announced the exclusive launch of the generic version of Reyataz, which is a registered trademark of Bristol-Myers Squibb (BMY) in the United States.
With global growth still subdued despite loose monetary policy and rock-bottom interest rates, the case for fiscal stimulus has become more compelling.
Fiscal policy has turned more expansionary, with stress on fiscal spending and monetary easing, thereby flooding the financial markets worldwide with huge liquidity.
In the past three decades, emerging market (EEM) economies grew rapidly, led by exports, which shifted current account balances from a deficit to a huge surplus.
The data from the Bureau of Labor Statistics shows that average hourly earnings have reached $21.45, up by 2.5% YoY, and represent the highest growth since January.
Even on the earnings yield basis, emerging markets look attractive with a yield of 8.4% compared to 6% for the S&P 500 and 6.7% for the MSCI EAFE Index.
In this series, we’ll see how investors can best seek to reduce volatility and capture opportunities by following diversification and selectivity as a long-term strategy.
